Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria

Epilepsy Research

Volumn 114, Issue , 2015, Pages 106-113

  Carmichael, Katie ^a   Nolan, Sarah J ^a   Weston, Jennifer ^a   Tudur Smith, Catrin ^a   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse events; CONSORT; Harms; Non randomised; Randomised controlled trial; Topiramate

Indexed keywords

TOPIRAMATE; ANTICONVULSIVE AGENT; FRUCTOSE;

ADVERSE OUTCOME; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FUNDING; HUMAN; INTERRATER RELIABILITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; AGING; ANALOGS AND DERIVATIVES; CHECKLIST; CHILD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPLICATION; FACTUAL DATABASE; FINANCIAL MANAGEMENT; METHODOLOGY; MULTICENTER STUDY (TOPIC); OBSERVER VARIATION; STANDARDS;

ADULT; AGING; ANTICONVULSANTS; CHECKLIST; CHILD; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EPILEPSY; FRUCTOSE; HUMANS; MULTICENTER STUDIES AS TOPIC; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC;

EID: 84931067973     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.04.019     Document Type: Article

References (17)

1. Altman D. Better reporting of randomised controlled trials: the CONSORT statement. BMJ 1996, 313:570-571.
2. Altman D., Schulz K., Moher D., Egger M., Davidoff F., Elbourne D., Gotzsche P., Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 2001, 134(8):663-694. CONSORT GROUP (Consolidated Standards of Reporting Trials).
3. Bagul N.B., Kirkham J.J. The reporting of harms in randomized controlled trials of hypertension using the consort criteria for harm reporting. Clin. Exp. Hypertens. 2012, 34(8):548-554.
4. Chan A.W., Krleza-Jeric K., Schmid I., Altman D.G. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health research. CMAJ 2004, 171(7):735-740.
5. Chou R., Helfand M. Challenges in systematic reviews that assess treatment harms. Ann. Intern. Med. 2005, 142:1090-1099.
6. Cohen J. Weighted kappa: nominal scale agreement provision for scaled disagreement of partial credit. Psychol. Bull. 1968, 70:213-220.
7. Golder S., Loke Y.K., Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011, 8(5):e1001026.
8. Han C., Kwak K., Marks D., Pae C., Wu L., Bhatia K., Masand P., Patkar A. The impact of the CONSORT statement on reporting of randomised clinical trials in psychiatry. Contemp. Clin. Trials 2009, 30:116-122.
9. Hodkinson A., Kirkham J.J., Tudur Smith C., Gamble C. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open 2013, 3:e003436.
10. Hopewell S., Altman D.G., Moher D., Schulz K.F. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials 2008, 9(1):20.
11. Ioannidis J., Evans S., Gotzsche P., O'Neill R., Altman D., Schulz K. Better reporting of harms in randomized trails: an extension of the CONSORT statement. Ann. Intern. Med. 2004, 141:781-788.
12. Plint A., Moher D., Morrison A., Schulz K., Altman D., Hill C., Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med. J. Aust. 2006, 185:263-267.
13. Sackett D.L., Tugwell P., Guyatt G.H. Clinical Epidemiology: A Basic Science for Clinical Medicine 1991, Little, Brown, Boston. 2nd ed.
14. Saini P., Loke Y., Gamble C., Altman D.G., Williamson P., Kirkham J.J. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 2014, 349:g6501.
15. Shukralla A., Tudur-Smith C., Powell G., Williamson P., Marson A. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res. 2011, 97:20-29.
16. Smith S., Wang A., Katz N., McDermott M., Burke L., Coplan P., Gilron I., Hertz S., Lin A., Rappaport B., Rowbotham M., Sampaio C., Sweeney M., Turk D., Dworkin R. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations. Pain 2013, 154:997-1008.
17. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann. Intern. Med. 2007, 147(8):573-577. STROBE Initiative.